Siirry sisältöön

Biovian in LabioTech’s news article – What Factors can Ease the Complexity of Viral Vector Production for Gene Therapies?

The article compares the manufacture of viral vectors with that of recombinant proteins and reveals how Biovian has developed a solution to address the continuing challenges in gene therapy production.

“Biovian has well over a decade of experience in both recombinant protein and viral vector contract development and manufacturing. The CDMO takes a so-called one-stop-shop approach to facilitate gene therapy production inefficiencies. In other words, all of the steps in recombinant protein and viral vector production can be done under one roof.”